New hope for sickle cell pain: canakinumab shows promise in kids

NCT ID NCT02961218

Completed Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called canakinumab (ACZ885) in 49 children and young adults aged 8-20 with sickle cell anemia. The goal was to see if it could reduce daily pain compared to a placebo. Participants rated their pain daily using a 0-10 scale, and researchers measured changes over 12 weeks. The trial was completed and focused on safety and pain relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE BETA0 THALASSEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inherited hemoglobinopathy sickle cell disease sickle cell-beta zero-thalassemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SICKLE CELL ANEMIA

Contacts and locations

Locations

Novartis Investigative Site

Atlanta, Georgia, 30329, United States
Novartis Investigative Site

Augusta, Georgia, 30912, United States
Novartis Investigative Site

Greenville, North Carolina, 27834, United States
Novartis Investigative Site

Toronto, Ontario, M5G 1X8, Canada
Novartis Investigative Site

Hamburg, 20246, Germany
Novartis Investigative Site

Afula, 1834111, Israel
Novartis Investigative Site

Johannesburg, Guateng, 2193, South Africa
Novartis Investigative Site

Adana, 01330, Turkey (Türkiye)
Novartis Investigative Site

Ankara, 06100, Turkey (Türkiye)
Novartis Investigative Site

Mersin, 33343, Turkey (Türkiye)
Novartis Investigative Site

Wolverhampton, Staffordshire, WS11 5XY, United Kingdom
Novartis Investigative Site

London, E1 1BB, United Kingdom
Novartis Investigative Site

London, NW1 2BU, United Kingdom
Novartis Investigative Site

London, SE1 7EH, United Kingdom
Novartis Investigative Site

London, SE5 9RS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.